Aurora Cannabis to Exit Consumer Markets Following Third-Quarter Loss

The company’s total revenue climbed to C$94.2 million, up from C$88.2 million in the prior year, surpassing the C$92.4 million projected by analysts. This growth was fueled largely by a 12% increase in global medical cannabis sales and a 27% surge in the company’s plant propagation division. However, these gains were offset by a sharp 48% decline in consumer cannabis revenue, a segment the company is now actively downsizing.

Beginning in the fiscal fourth quarter, Aurora will initiate a phased exit from specific consumer markets. Management noted that the high costs and thin margins associated with recreational retail have weighed on the balance sheet. By narrowing its focus, the company expects to see a significant reduction in sales, general, and administrative expenses.

Prioritizing Higher-Margin Medical Growth

CEO Miguel Martin stated that the refocusing initiative is designed to bolster adjusted EBITDA in the coming quarters. Martin emphasized that the strength of the medical business provides a foundation for future acquisitive opportunities to expand capacity. The company’s adjusted EBITDA reached C$18.5 million, according to the report, narrowly edging out the C$18.4 million forecast by FactSet.

The transition marks a definitive end to the aggressive recreational expansion strategies that once defined the Canadian cannabis landscape. Aurora now joins several peers in retrenching to specialized sectors where pricing power remains more resilient against market saturation and price compression in the retail space.